# Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

> **NCT05215548** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Taiwan University Hospital** · enrollment: 100 (estimated)

## Conditions studied

- NSCLC Stage IV

## Interventions

- **PROCEDURE:** therapeutic thoracic surgery
- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT05215548
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-27
- **Primary completion:** 2026-10
- **Final completion:** 2027-10
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05215548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05215548, "Primary Tumor Resection With EGFR TKI for Stage IV NSCLC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05215548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*